Company intelligence / Profile preview

Biospring Medical

Ownership: Private
Development stage: Commercial

Overview

Biospring Medical Co., Ltd. is a Taiwan-based private biotech company founded in 2017. The company develops advanced mesenchymal stem cell therapies derived from placenta choriodecidual membranes. Its lead program targets adult respiratory distress syndrome and has reached Phase 1 clinical trials. No additional pipeline programs or late-stage assets are reported publicly. The company's focus lies at the intersection of regenerative medicine and severe pulmonary disease, leveraging placental MSCs for potential tissue repair and immunomodulation effects.

Therapeutic areas: Pulmonology
Modalities: Mesenchymal stem cell therapyCell therapy
Industry: Biotech

Drug pipeline

1 asset

MatriPlax

Beyond the preview

Go deeper on Biospring Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biospring Medical.

Explore the full profile